Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

Scotland & Northern England
17 May 2013 20:08



UK
17 May 2013 16:41



N1
17 May 2013 15:21


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
During the recruitment process, I felt that I was supported throughout and that there was always the opportunity to discuss options or issues with an informed individual.
Stuart, 2011

Novo Nordisk awards journalists for diabetes awareness boost

30 August 2007 00:00 in Pharmaceutical Company Product News


Novo Nordisk has announced the presentation of its Media Prize 2007 to two journalists for their work in increasing public awareness of diabetes.

The accolade was given to Argentina's Gabriela Navarra for a print article and Michael Kefalogiannis from Greece for his TV feature on the condition.

Printed in weekly magazine La Nacion Revista, Ms Navarra's article addressed how patients deal with their condition, while also exploring the discovery of insulin and new treatments and exploding a number of myths about the disease.

In his TV feature on weekly show Health for All, Mr Kefalogiannis presented scientific facts about the condition for the lay-person, exploring issues relating to both types one and two of the condition, undiagnosed diabetes, pre-diabetic symptoms and diabetes in pregnancy.

Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk, said: "The majority of cases of type two diabetes are preventable if people understand what causes the disease and what can be done to prevent it.

"The media play a crucial role in creating this awareness."

He added that the entrants to this year's media prize competition provide exceptional examples of how the media can boost awareness of diabetes and help prevent rising incidence of the condition.

In May 2007, Novo Nordisk unveiled its $200 million (100 million pound) insulin manufacturing site in Brazil, its largest facility outside its base country of Denmark.

Other news stories from 30/08/2007

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd